GHK-Cu (Copper Peptide) 50mg

GHK-Cu is the copper(II) complex of the naturally occurring human tripeptide glycyl-L-histidyl-L-lysine, often written Gly-His-Lys or simply GHK. The peptide itself was first identified in human plasma in the early 1970s, and the copper-bound form was recognized shortly afterward as the biologically relevant species in many of the contexts where the tripeptide's activity was characterized. The combination of a defined small peptide sequence with a specific copper coordination chemistry makes GHK-Cu unusual among research peptides — it is as much a coordination compound as it is a peptide, and most of its biology depends on the copper that the peptide carries.

The scientific interest in GHK-Cu sits at the intersection of copper biochemistry, tissue repair biology, gene expression research, and cosmetic peptide chemistry. Copper is an essential trace element that participates as a cofactor in numerous enzymes (including superoxide dismutase, cytochrome c oxidase, and lysyl oxidase) and in regulatory roles where its redox activity and metal-binding properties become biologically consequential. GHK is a high-affinity copper-binding peptide that has been proposed to function as a physiological copper carrier and delivery agent — moving copper between proteins and binding sites in plasma and in tissues, with downstream consequences for processes that depend on copper availability and on GHK-dependent signaling.

The research conversation around GHK-Cu has included reports of effects on tissue repair, on collagen and extracellular matrix gene expression, on antioxidant gene networks, on hair follicle biology, and on broader gene expression patterns characterized in transcriptomic studies. In the cosmetic peptide world, GHK-Cu has been a long-standing ingredient in topical skin and hair preparations and has substantial commercial use in that context. In the research peptide world, the compound is studied as a tool for asking questions about copper-dependent biology and about the gene-regulatory effects of the tripeptide-copper complex.

This page is a plain-English educational reference for readers who want to understand what GHK-Cu actually is, where it came from, what its proposed mechanisms in the published research are, and where it sits in the broader research peptide landscape. It is not a medical guide, it does not describe a treatment for any individual, and it makes no claims about cosmetic, wound healing, or hair growth effects in people. GHK-Cu supplied as a research peptide is intended for laboratory and analytical purposes only, and the entire discussion below is framed within that context.

Throughout the page, terms that recur in GHK-Cu research — coordination complex, copper(II), lysyl oxidase, decorin, tropoelastin — are defined as they come up, and the glossary at the end collects them for easy reference. The FAQ section addresses the questions that most often arise about GHK-Cu specifically and about copper-peptide research more generally.

GHK-Cu is the copper(II) complex of the human tripeptide glycyl-L-histidyl-L-lysine (Gly-His-Lys). The free peptide has the sequence H-Gly-His-Lys-OH and a molecular mass of approximately 340 daltons; the copper-bound complex adds one copper(II) ion plus typically a coordinated water or hydroxide molecule, depending on conditions, for a total complex mass in the range of approximately 400-420 daltons. The peptide is endogenously present in human plasma at low nanomolar concentrations in young adults, with the concentration declining with age (a finding from the original GHK research literature that is frequently cited in discussions of the compound).

The structural basis of copper binding in GHK-Cu is well characterized. The N-terminal amino group of glycine, the imidazole side chain of histidine, and the deprotonated amide nitrogen of the Gly-His peptide bond together coordinate the copper(II) ion in a square-planar (or square-pyramidal with axial water) geometry. The lysine side-chain amino group is not directly involved in copper coordination but contributes to the overall charge and solubility of the complex. The binding affinity of GHK for copper(II) is extremely high — in the picomolar range for the apparent dissociation constant at physiological pH — which means that in the presence of physiological copper, free GHK and copper-bound GHK readily interconvert with the bound form dominating.

The discovery that GHK has high copper-binding affinity, and that the copper-bound form is the biologically relevant species in many contexts, came from the work of Loren Pickart and colleagues in the early 1970s. Pickart originally isolated GHK as the "growth factor" responsible for restoring proliferation to liver cells in older-donor plasma, and the copper-binding role was recognized shortly afterward as the molecular basis for many of the activities attributed to the peptide. This insight reframed GHK from a "growth-stimulating peptide" into a "copper-delivery peptide" — a coordination chemistry framing that has guided much of the subsequent research.

The biological roles proposed for GHK-Cu in the research literature have included effects on collagen and extracellular matrix synthesis (through copper-dependent enzymes including lysyl oxidase), on antioxidant gene networks (where copper participates in both prooxidant and antioxidant chemistry depending on context), on growth factor activity in tissue repair, on hair follicle biology, and on broader transcriptional programs characterized in microarray and RNA-seq studies. The proposed mechanisms are multiple and interconnected, reflecting the broad biological footprint of copper-dependent biology in mammalian tissues.

It is worth being specific about what GHK-Cu is not. It is not a growth hormone or a hormone in the classical sense. It is not a receptor agonist with a single mapped target receptor in the way most peptide drugs are; instead, its proposed mechanism involves multiple downstream effects mediated by copper coordination chemistry and tripeptide-specific interactions with various proteins. It is not the same as AHK-Cu, a related tripeptide-copper complex (Ala-His-Lys with copper) that shares the histidine-anchored coordination chemistry but has different specific biological characterization. And it is not an approved medicine in major pharmaceutical regulatory jurisdictions, though it has substantial regulated use in cosmetic ingredient frameworks.

The history of GHK-Cu begins with Loren Pickart's doctoral and postdoctoral research in the early 1970s on factors in human plasma that affect cell proliferation. Pickart observed that plasma from older human donors had reduced ability to support cell proliferation in liver cell culture compared to plasma from younger donors, and he set out to identify the factor responsible for the proliferation-supporting activity. Through fractionation and characterization, he isolated a tripeptide active component and determined its sequence as Gly-His-Lys. This identification was published in 1973 and represents the foundational paper of the GHK research literature.

Shortly after the original identification, the copper-binding properties of GHK were recognized and the role of the copper-bound form (GHK-Cu) in many of the original activities was established. The reframing of GHK from "growth factor" to "copper-delivery peptide" was an important conceptual development that connected the peptide to broader research on copper biochemistry. Through the 1970s and 1980s, the basic coordination chemistry of GHK with copper(II) was characterized in detail, with the geometry and binding affinity established by spectroscopic and equilibrium methods.

Through the 1980s and 1990s, GHK-Cu attracted substantial research interest in the context of wound healing and tissue repair. Studies in animal models of wound healing reported accelerated wound closure, increased collagen deposition, improved scar quality, and effects on the broader extracellular matrix remodeling process. The mechanism was proposed to involve copper-dependent enzymes (notably lysyl oxidase, which catalyzes the cross-linking of collagen and elastin and requires copper as a cofactor), GHK-specific effects on growth factor activity, and downstream gene-expression effects in fibroblasts and other tissue-repair-relevant cell types.

In parallel with the wound healing research, GHK-Cu emerged as a prominent ingredient in cosmetic peptide preparations through the 1990s and 2000s. Topical formulations containing GHK-Cu became widely used in skin care contexts, with claims and supporting research focused on collagen synthesis, skin remodeling, and the broader anti-aging cosmetic research domain. The compound also appeared in hair care formulations targeting hair follicle research endpoints. The cosmetic ingredient regulatory framework, distinct from the pharmaceutical regulatory framework, governs these uses in most jurisdictions.

The 2000s and 2010s brought substantial expansion of the GHK-Cu literature through transcriptomic studies. Microarray and RNA-seq investigations of cells exposed to GHK-Cu identified broad patterns of gene expression changes — affecting hundreds or thousands of genes in some studies — touching on collagen and extracellular matrix genes, antioxidant defense genes, DNA repair genes, immune-related genes, and others. The interpretation of these transcriptomic findings has been a continuing area of discussion, with some researchers viewing the broad effects as evidence of a regulatory function and others viewing them with caution given the difficulty of distinguishing direct effects from secondary consequences in such broad gene-expression landscapes.

Loren Pickart's continuing role in promoting GHK-Cu through the decades following the original discovery has been a distinctive feature of the literature. Pickart's own publications and conceptual frameworks have shaped much of the discourse around the compound, and the research community working specifically on GHK-Cu has had substantial overlap with Pickart's collaborations. The mainstream copper-biology research community and the broader peptide research community have engaged with the GHK-Cu literature at various points, but the depth of independent characterization outside the Pickart-affiliated research has been variable.

Important milestones in the GHK-Cu literature include the original 1973 identification of GHK as a plasma-derived cell proliferation factor, the recognition of the copper-binding role in the late 1970s, the wound healing and collagen research of the 1980s and 1990s, the establishment of GHK-Cu as a cosmetic ingredient in the 1990s and 2000s, and the transcriptomic expansion of the research literature in the 2000s and 2010s.

The science of GHK-Cu is grounded in three interconnected areas: copper biochemistry in mammalian tissues, the coordination chemistry of histidine-containing peptides, and the cellular and tissue-level biology in which the tripeptide and the copper it carries have been studied. Understanding the compound requires touching on each.

• GHK-Cu is the copper(II) complex of the human tripeptide Gly-His-Lys, with picomolar copper-binding affinity.
• The peptide binds copper through the N-terminal amine, histidine imidazole, and Gly-His amide nitrogen in a square-planar geometry.
• Published research includes effects on collagen and extracellular matrix biology, partly via copper-dependent lysyl oxidase.
• Broad transcriptomic effects on hundreds to thousands of genes have been reported, with interpretation continuing.
• The compound has substantial cosmetic-ingredient regulated use distinct from any pharmaceutical approval.

Structurally, GHK is a linear tripeptide with the sequence H-Gly-His-Lys-OH and a molecular mass of approximately 340 daltons in the free-acid form. The copper(II) complex adds one copper ion plus typically a coordinated water or hydroxide molecule, depending on conditions, giving the complex an overall mass in the range of approximately 400-420 daltons. The peptide has no disulfide bonds, no cyclization, and no covalent modifications beyond the standard amide bond backbone.

The copper coordination geometry is the defining structural feature of GHK-Cu. The N-terminal glycine amino group donates one nitrogen ligand to the copper, the imidazole nitrogen of the histidine side chain donates a second nitrogen ligand, and the deprotonated amide nitrogen of the Gly-His peptide bond donates a third nitrogen ligand. These three N-donors occupy three of the four equatorial coordination positions of the square-planar copper(II) center. The fourth equatorial position is typically occupied by a water molecule, a hydroxide ion, or a fourth donor from the peptide depending on conditions. An axial position above or below the square plane can be occupied by a more loosely bound water molecule, giving a square-pyramidal geometry in some conditions.

The histidine residue is the key structural anchor of the complex. The combination of the N-terminal amine, the histidine imidazole, and the intervening amide nitrogen is a recurrent high-affinity copper-binding motif in peptide biochemistry — it appears in human serum albumin's N-terminal copper-binding site, in various other copper-binding peptides, and in synthetic copper-binding peptide design. The histidine at position 2 of GHK is therefore not interchangeable; substitution with other residues dramatically reduces copper-binding affinity and alters the complex's properties.

The lysine residue at position 3 contributes to the overall charge and solubility of the molecule but is not directly involved in copper coordination. The positively charged lysine side chain at physiological pH may play a role in interactions with negatively charged cellular surfaces, with extracellular matrix components, and with DNA, and may contribute to the cellular uptake and tissue distribution properties of the complex.

Stability characteristics of GHK-Cu are generally favorable. Lyophilized material stored sealed at deep-freeze temperatures away from light is considered stable for extended periods. The complex is sensitive to reducing conditions that would convert copper(II) to copper(I) and to chelating agents that would displace the copper from the GHK ligand; standard laboratory storage conditions avoid both. In aqueous solution at physiological pH, the complex is the dominant species in the presence of any nontrivial copper, but in copper-free conditions the apo-peptide form predominates.

Research-grade GHK-Cu is produced through solid-phase peptide synthesis of the tripeptide followed by copper complexation. The synthesis of the free tripeptide is straightforward; copper complexation is typically performed by mixing the tripeptide with copper(II) salts (chloride, acetate, or sulfate) at controlled pH, with the resulting complex purified by chromatography. The characteristic blue color of copper(II) complexes (with absorption near 525 nm) provides a convenient spectroscopic handle for monitoring complexation. A Certificate of Analysis for research-grade GHK-Cu typically reports the peptide sequence and purity, the copper content (often by atomic absorption or ICP-MS), and the residual moisture and counterion information.

GHK-Cu has been used as a research tool across several connected themes — wound healing and tissue repair, extracellular matrix and collagen biology, antioxidant and copper biology, gene expression studies, hair follicle research, and cosmetic peptide chemistry. None of the areas described below represents a therapeutic use in individuals, and none should be read as suggesting clinical benefit; they are research directions where the compound has been useful as an experimental probe.

• Wound healing and tissue repair research
• Extracellular matrix, collagen, and lysyl oxidase biology
• Transcriptomic and gene-expression studies
• Copper biochemistry and antioxidant biology research
• Hair follicle biology research
• Cosmetic peptide chemistry and topical formulation

GHK-Cu sits in a family of small copper-binding peptides, and is best compared with several related compounds to clarify its specific identity within that family.

The closest comparison is with AHK-Cu (Ala-His-Lys with copper), a related copper-binding tripeptide that shares the histidine-anchored coordination chemistry but has alanine rather than glycine at position 1. The alanine substitution does not abolish copper binding but does modify the geometry, the binding affinity, and the biological characterization of the complex. AHK-Cu is studied in some of the same research contexts as GHK-Cu, particularly in hair follicle research.

A second comparison is with the N-terminal copper-binding site of human serum albumin, which uses the sequence Asp-Ala-His-Lys (DAHK) at the N-terminus of the albumin protein to bind copper(II) through the same general N-terminal/histidine/amide-nitrogen coordination geometry. Albumin is the major plasma copper-binding protein and exchanges copper with GHK in the proposed physiological copper-delivery cycle. Synthetic DAHK and related peptide fragments are studied as research tools alongside GHK-Cu.

GHK-Cu is also compared with non-copper variants of the same tripeptide. The apo-peptide GHK (without copper) has reduced or absent activity in many of the contexts where the copper-bound form has been characterized, reflecting the copper-dependent nature of much of the biology. Studies that compare GHK-Cu with apo-GHK help establish which effects depend on the copper and which (if any) depend on the peptide alone.

A broader comparison is with other research peptides in the tissue-repair and cosmetic-bioactive space. BPC-157, a 15-amino-acid stable gastric peptide fragment, is the most prominent research peptide in tissue-repair conversations; it has an entirely different sequence, structure, and proposed mechanism from GHK-Cu, with no copper involvement. TB-500 (the thymosin beta-4 fragment) and various growth-factor-related peptides also appear in tissue-repair research literatures. GHK-Cu's distinctive feature in this broader landscape is its dependence on copper coordination chemistry rather than on direct receptor engagement.

Finally, GHK-Cu should be distinguished from cosmetic small molecules and other cosmetic peptides — retinoids, glycolic acid, palmitoyl peptides, acetyl peptides, and various other cosmetic-ingredient classes. GHK-Cu is one of several copper-peptide complexes in the cosmetic ingredient literature, and its specific identity (tripeptide with the GHK sequence, copper(II) complex, the characteristic blue color and coordination geometry) distinguishes it within that broader cosmetic peptide family.

The GHK-Cu literature gives a particular impression: a naturally occurring human tripeptide with high-affinity copper-binding chemistry, identified in the early 1970s, developed across five decades through wound-healing, extracellular-matrix, copper-biology, and cosmetic-research arms, and present in both the research peptide market and the cosmetic ingredient market in substantial regulated use. The compound's place in the broader peptide research landscape is distinctive: it is as much a coordination compound as it is a peptide, and most of its biology depends on the copper that the peptide carries.

The conceptual foundation of GHK-Cu is well grounded. The coordination chemistry is firmly established by spectroscopic, structural, and equilibrium methods. The role of copper in extracellular matrix biology through copper-dependent enzymes like lysyl oxidase is independently well-characterized. The connection between GHK-Cu, copper delivery to copper-dependent enzymes, and downstream effects on collagen and matrix biology has substantial supporting research across multiple decades.

The breadth of the transcriptomic effects is one of the more striking and more controversial features of the literature. Reports of gene-expression changes affecting thousands of genes at certain doses and exposure times are unusual in the peptide literature, and the interpretation has been an area where the more enthusiastic readings (the compound has broad regulatory activity across many cellular processes) and the more cautious readings (broad gene-expression effects can reflect secondary consequences and may not all be specific or mechanism-based) coexist in the discourse. Independent characterization at the level of detailed mechanism connecting the tripeptide-copper complex to specific transcriptional regulation has been more limited than the descriptive transcriptomic findings themselves.

The cosmetic-ingredient use of GHK-Cu represents a substantial and well-regulated application of the compound, governed by cosmetic ingredient regulatory frameworks distinct from pharmaceutical approval. The commercial cosmetic use does not constitute approval of the compound as a medicine and does not establish efficacy claims at the level of evidence required for pharmaceutical regulation. The two regulatory frameworks have different evidentiary standards and different scope of allowed claims.

Methodologically, GHK-Cu research has used cell-culture systems (primarily fibroblasts, keratinocytes, and dermal papilla cells), animal models (rodent wound-healing models predominantly), human clinical-research studies in cosmetic contexts, and analytical biochemistry approaches. The pharmacokinetic and tissue-distribution profile of the compound has been characterized at varying levels of detail across the different research contexts. The mechanistic resolution at the level of specific protein-protein interactions and signaling pathway activation has been less complete than for some other research peptides with single-receptor mechanisms.

Open questions in the GHK-Cu field include the specific cellular targets responsible for the broad transcriptomic effects, the relationship between the copper-delivery role and the direct peptide-only effects (if any), the comparative biology of GHK-Cu and related copper-peptides in defined cellular contexts, and the translation of cell-culture and animal-model findings to clinical-research endpoints under controlled study conditions.

For students, researchers, and curious readers approaching GHK-Cu for the first time, the most accurate framing is that of a naturally occurring copper-binding tripeptide with substantial research literature across five decades, with well-established coordination chemistry and well-grounded connections to copper-dependent extracellular matrix biology, with substantial cosmetic-ingredient regulated use, and with ongoing research conversations about the breadth and specificity of the broader transcriptomic effects. The compound is supplied for laboratory and analytical use only as a research peptide, and educational discussion of it needs to stay within that framing rather than drift into cosmetic or therapeutic claims about effects in people who purchase the compound.

GHK-Cu is the copper(II) complex of the naturally occurring human tripeptide glycyl-L-histidyl-L-lysine. The free tripeptide was first identified in human plasma in 1973 by Loren Pickart as a factor supporting cell proliferation in liver cell cultures, and the copper-binding role of the peptide was recognized shortly afterward as the molecular basis for many of the activities attributed to GHK. The complex binds copper through the N-terminal amine, the imidazole nitrogen of histidine, and the deprotonated amide nitrogen of the Gly-His peptide bond, forming a stable high-affinity coordination geometry.

The biological footprint of GHK-Cu in the published research includes copper-dependent extracellular matrix processes (notably through the copper-dependent enzyme lysyl oxidase, which cross-links collagen and elastin), broad effects on gene expression characterized in transcriptomic studies, antioxidant and redox-related effects connected to copper biochemistry, effects in wound-healing and tissue-repair research models, and effects in hair follicle biology research. The mechanisms are multiple and interconnected rather than reducing to a single receptor or pathway, reflecting the broad biological footprint of copper-dependent biology.

The compound has substantial cosmetic-ingredient regulated use in topical preparations under the relevant cosmetic regulatory frameworks, distinct from any pharmaceutical approval. In the research peptide context, GHK-Cu is a tool for studying copper biochemistry, extracellular matrix biology, and the broader effects characterized in the transcriptomic literature.

This page treats GHK-Cu as an educational subject and a research peptide. It is supplied for laboratory and analytical use only. Nothing in the discussion above constitutes medical advice, describes a treatment for any individual, or makes cosmetic or therapeutic claims about effects in people who purchase the compound for research. The framing throughout reflects the compound's actual status as a research peptide of substantial laboratory interest with a well-characterized coordination chemistry, well-grounded connections to copper-dependent extracellular matrix biology, and a distinctive cosmetic-ingredient regulated use that operates under different evidentiary frameworks from pharmaceutical approval.